- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Use of SGLT2 inhibitors tied to lower dementia risk in older people with type 2 diabetes: Study
Canada: The new use of sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with dipeptidyl peptidase 4 (DPP-4) inhibitors confers 20% lower dementia risk in older people with type 2 diabetes, a recent study published in Diabetes Care has stated.
SGLT2 inhibitors are a class of prescription medications approved by the FDA to be used with exercise and diet to lower blood sugar in adults with type 2 diabetes. The drugs in this class include empagliflozin, dapagliflozin, and canagliflozin. DPP-4 inhibitors, also called gliptins, are a class of oral diabetic medications which are FDA-approved for treating type 2 diabetes in adults. FDA-approved DPP inhibitors include linagliptin, saxagliptin, alogliptin, and sitagliptin.
It is known that type 2 diabetes raises the risk of dementia, but there is a lack of clear evidence to recommend interventions that can lower this risk. For this purpose, Walter Swardfager from the University of Toronto in Toronto, Ontario, Canada, and colleagues aimed to determine whether the new use of SGLT2 inhibitors compared with DPP-4 inhibitors was linked with a lower risk of dementia in a population-based retrospective cohort study.
The cohort included Ontario residents aged ≥66 who were new users of a DPP-4 inhibitor or an SGLT2 inhibitor from 1 July 2016 - 31 March 2021. A validated algorithm for Alzheimer's disease and related dementias was used to identify incident dementia. Adjusted hazard ratios (aHR) for time to incident dementia were obtained using Propensity-score weighted Cox proportional hazards models.
The observation window was initiated at 1-year lag time from cohort entry to address disease latency and reverse causality. The primary analysis followed the intention-to-treat exposure definition, and secondary as-treated research was conducted.
The study led to the following findings:
- Among 106,903 individuals, SGLT2 inhibitors compared with DPP-4 inhibitors were associated with a lower risk of dementia (14.2/1,000 person-years; aHR 0.80) over a mean follow-up of 2.80 years from cohort entry.
- When stratified by different SGLT2 inhibitors, dapagliflozin exhibited the lowest risk (aHR 0.67), followed by empagliflozin (aHR 0.78), whereas canagliflozin showed no association (aHR 0.96).
- The as-treated analysis observed a more significant association (aHR 0.66) than the intention-to-treat analysis.
"The results indicate an association between SGLT2 inhibitors and lower dementia risk in older people with type 2 diabetes," the authors conclude. "Randomized controlled trials are warranted."
Reference:
Che-Yuan Wu, Carina Iskander, Christa Wang, Lisa Y. Xiong, Baiju R. Shah, Jodi D. Edwards, Moira K. Kapral, Nathan Herrmann, Krista L. Lanctôt, Mario Masellis, Richard H. Swartz, Hugo Cogo-Moreira, Bradley J. MacIntosh, Jennifer S. Rabin, Sandra E. Black, Refik Saskin, Walter Swardfager; Association of Sodium–Glucose Cotransporter-2 Inhibitors with Time to Dementia: A Population-Based Cohort Study. Diabetes Care 2022; dc221705. https://doi.org/10.2337/dc22-1705
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751